Crispr Therapeutics Ag Stock Market Value
| CRSP Stock | USD 46.29 0.97 2.05% |
| Symbol | Crispr |
Crispr Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share 2.446 | Quarterly Revenue Growth (0.99) | Return On Assets (0.1) | Return On Equity (0.13) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Crispr Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Crispr Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Crispr Therapeutics.
| 12/02/2022 |
| 11/21/2024 |
If you would invest 0.00 in Crispr Therapeutics on December 2, 2022 and sell it all today you would earn a total of 0.00 from holding Crispr Therapeutics AG or generate 0.0% return on investment in Crispr Therapeutics over 720 days. Crispr Therapeutics is related to or competes with Beam Therapeutics, Editas Medicine, Caribou Biosciences, Verve Therapeutics, Intellia Therapeutics, Fate Therapeutics, and Regeneron Pharmaceuticals. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using it... More
Crispr Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Crispr Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Crispr Therapeutics AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 16.95 | |||
| Value At Risk | (4.61) | |||
| Potential Upside | 4.96 |
Crispr Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crispr Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Crispr Therapeutics' standard deviation. In reality, there are many statistical measures that can use Crispr Therapeutics historical prices to predict the future Crispr Therapeutics' volatility.| Risk Adjusted Performance | 0.0024 | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.02) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Crispr Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Crispr Therapeutics Backtested Returns
Crispr Therapeutics secures Sharpe Ratio (or Efficiency) of -0.015, which signifies that the company had a -0.015% return per unit of risk over the last 3 months. Crispr Therapeutics AG exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Crispr Therapeutics' Mean Deviation of 1.97, standard deviation of 2.81, and Risk Adjusted Performance of 0.0024 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.65, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Crispr Therapeutics will likely underperform. At this point, Crispr Therapeutics has a negative expected return of -0.0415%. Please make sure to confirm Crispr Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Crispr Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Crispr Therapeutics AG has insignificant reverse predictability. Overlapping area represents the amount of predictability between Crispr Therapeutics time series from 2nd of December 2022 to 27th of November 2023 and 27th of November 2023 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Crispr Therapeutics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Crispr Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 106.41 |
Crispr Therapeutics lagged returns against current returns
Autocorrelation, which is Crispr Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Crispr Therapeutics' stock expected returns. We can calculate the autocorrelation of Crispr Therapeutics returns to help us make a trade decision. For example, suppose you find that Crispr Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Crispr Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Crispr Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Crispr Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Crispr Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Crispr Therapeutics Lagged Returns
When evaluating Crispr Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Crispr Therapeutics stock have on its future price. Crispr Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Crispr Therapeutics autocorrelation shows the relationship between Crispr Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Crispr Therapeutics AG.
Regressed Prices |
| Timeline |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.35 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.35 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.35 | PALI | Palisade Bio | PairCorr |
| 0.33 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.